The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Interesting interviews video clip / tweet courtesy of :
https://twitter.com/111BEN_111/status/1759186470303154315
"Ben
@111BEN_111
·
10m
#AVCT
Two very interesting interviews
The future of oncology is “targeted cancer killing agents”. The pre|CISION technology exquisitely targets FAPa, the technology has many clinical and commercial advantages to ADCs
Be confident in what you "
LLP thanks - Guess first priority for Liily/PB is to get radiopharmaceuticals approved . canSEEK™ enabled targets are still not disclosed . AVA6000 data findings might encourage them to accelerate FAP related programs & maybe renegotiate licence .
"The agreement provides POINT with an exclusive license to the pre|CISION technology for use in the first radiopharmaceutical prodrug the company intends to develop, and a non-exclusive license to the pre|CISION™ platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals. "
Avacta licence CanSEEK™ to PB/Lilly : CanSEEK™ is a next stage development program but " has the potential to make treatments even more precise, expanding their therapeutic index, and enabling the use of new, more powerful medical isotopes "
Meanwhile current Tufts & PB/Lilly Program PNT2004 ( clinical candidate -PNT6555) pre-clinical FAP data .
"The overexpression of fibroblast activation protein-a (FAP) in solid cancers relative to levels in normal tissues has led to its recognition as a target for delivering agents directly to tumors. Radiolabeled quinoline-based FAP ligands have established clinical feasibility for tumor imaging, but their therapeutic potential is limited due to suboptimal tumor retention, which has prompted the search for alternative pharmacophores. One such pharmacophore is the boronic acid derivative N-(pyridine-4-carbonyl)-D-Ala-boroPro, a potent and selective FAP inhibitor (FAPI)
CONCLUSION
The preclinical results support the advancement of PNT6555 to the “FAPi Radioligand Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Dosimetry of [Lu-177]-PNT6555: A Dose Escalation Study for Treatment of Patients with Select Solid Tumors (FRONTIER)” (ClinicalTrials.gov identifier NCT05432193).
https://jnm.snmjournals.org/content/jnumed/65/1/100.full.pdf
Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-α (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors
---------------
Preclinical Development of PNT6555, a Boronic Acid–Based, Fibroblast Activation Protein-α (FAP)–AP-Positive Tumors
https://classic.clinicaltrials.gov/ct2/results?cond=NCT05432193&term=&cntry=&state=&city=&dist=
https://facultyprofiles.tufts.edu/william-bachovchin/publications
https://www.pointbiopharma.com/our-products/pipeline
https://www.pointbiopharma.com/our-products/pipeline/canseek
Good Morning
Maybe just semantics : Think the science works
"can be used to modify a chemotherapy"---"reduce the side effects and improve the overall safety and therapeutic potential of these powerful anti-cancer treatments."
------------
RNS Dated 22nd Jan 2024
"The pre|CISION? platform modifies chemotherapy to be activated only in the tumour tissue, reducing systemic exposure and toxicity. This is achieved by harnessing an enzyme called FAP which is highly upregulated in most solid tumours compared with healthy tissues, turning chemotherapy into a "precision medicine". The lead pre|CISION? programme, AVA6000 a tumour activated form of doxorubicin, is in Phase 1 studies and has shown dramatic improvement in safety compared with standard doxorubicin, and early signs of clinical activity."
RNS Dated 16th Feb 2024
"The pre|CISION™ tumour targeting platform can be used to modify a chemotherapy in order to selectively release the active drug in tumour tissue thereby reducing the systemic exposure that causes damage to healthy tissues. pre|CISION™ modified chemotherapies are designed to reduce the side effects and improve the overall safety and therapeutic potential of these powerful anti-cancer treatments."
Fyi
https://www.linkedin.com/feed/update/urn:li:activity:7163859737699147776/
David Wilson Avacta Chief Commercial Officer | Driving Global IVD Business Growth
likes this
"Launch Diagnostics LimitedLaunch Diagnostics Limited
1,463 followers1,463 followers
1h • 1h •
The BioCLIA 500 and BioCLIA 6500 instruments from HOB are setting a new standard in autoimmune diagnostic testing.
The BioCLIA instruments use Chemiluminescent Immunoassay (CLIA) technology to deliver accurate and rapid results.
Experience seamless workflow with true random access and continuous loading capabilities. STAT positions ensure urgent testing requirements are met.
For more information go to https://lnkd.in/ebJfDnvx or contact enquiries @launchdiagnostics.com
LD liked this report on linkedin : Appreciate some here think Diagnostics apparently brings little value but as long as it remains part of Avacta balance sheet -any profitable revenue contribution from Coris/LD surely a good thing .
(Sorry folks just have to accept until advised otherwise -acquisitions repayments will be by issuing shares - )
Anyway huge global market for Coris/LD products .
"The global demand for Infectious Diseases Molecular Diagnostics Market is presumed to reach the market size of nearly USD 64.17 BN by 2028 from USD 45 BN in 2021 with a CAGR of 5.2% under the study period 2022 - 2028."
https://www.valuemarketresearch.com/report/infectious-diseases-molecular-diagnostics-market
MSK " A Phase 1a Study of AVA6000 in People with Solid Tumors "
https://www.mskcc.org/cancer-care/clinical-trials/22-428
"AVA6000 is a “prodrug,” meaning it remains inactive until it reaches the site of the cancer. Because of the way AVA6000 works, it may be useful for treating cancer with fewer side effects than doxorubicin. AVA6000 is given intravenously (by vein)."
Mind you standard dox "If you are prescribed doxorubicin it will only be given to you by doctors or nurses experienced in giving chemotherapy. This medicine will be given to you by a doctor or nurse through a drip (infusion) into a vein. Your doctor will decide what dose to give and the number of days treatment you will receive depending on your condition."
Complete audio presentation "Targeting the Tumour Microenvironment Redefined "
https://www.youtube.com/watch?v=eqj0hhgmX6U
Good Morning : The science does work
https://avacta.com/wp-content/uploads/2023/12/AVA6000-Data-Release-13-December.pdf
Courtesy TTB https://twitter.com/tom_the_bomb__/status/1757159918618976330
Nice snapshot audio video CC explains - it works "Targeting the Tumour Microenvironment Redefined "
"Shrinking tumours ✅
Staying in tumour shrinkage ✅
Stabilising the disease for a prolonged period of time ✅
Favourable safety ✅
Responses that last for time ✅
Not experiencing problematic toxicity ✅
——
One day everyone will know about #AVCT’s preCISION."
Just added a few more takes my AVCT investment to £55,366 sadly currently down paper deficit -18.30% anyway as CC says "We will win. Together." Look foward to seeing Avacta asset IP /market cap value move northwards at some stage in the near future .
Good luck everyone .
FYI
"Christina Coughlin
@coughlin582
So important. Our scientists featured here are a critical part of our R&D efforts. We are proud of their efforts. Each featured has made critical discoveries in their field.
And so tonight we move forward in our quest. We will win. Together.
#LetsDoThis
#WeWillDefeatCancer"
Nice to read Avacta Ladies scientists focus is working towards better treatments for patients - nearly there me thinks .
--------------------
"working on new treatments that could really help patients, which is very exciting.
A breakthrough in cancer treatment represents a glimmer of hope for patients and their loved ones
Knowing that the work I do will directly impact patient outcome – improving survival and quality of life
exemplified by the excellent progress of our clinical candidate AVA6000.
whilst contributing to the science that will one day help improve patients’ lives."
How about stools : LD manufactuer
"VIRCELL S.L.VIRCELL S.L.
13,723 followers13,723 followers
5d • 5d •
Follow
Exciting news! We've got great results from our internal assessment comparing the HELICOBACTER PYLORI Ag VIRCLIA® MONOTEST with other top diagnostic tests in the market. Check out the study right here and stay tuned for more updates.
The new HELICOBACTER PYLORI Ag VIRCLIA® MONOTEST is a flexible and fully automated CLIA solution for stool antigen detection. Take advantage of its fast and easy pre-analytical treatment, without centrifugation.
https://lnkd.in/dMvvuNX6
#vircell #VirClia #CLIA #hpylori #helicobacterpylori #serology #diagnostics #infectiousdiseases #stoolsamples #empowerlabs #health
More coverage
Anatolia GeneworksAnatolia Geneworks
4,671 followers4,671 followers
1d • 1d •
Follow
The World Health Organization (WHO) draws attention to the increase in measles cases in Europe.
"The World Health Organization (WHO) draws attention to the increase in measles cases in Europe.
According to data from 41 European countries, the number of cases rose from 941 in 2022 to 42,200 in 2023, with a 45-fold increase. The European region experienced more than 200,000 hospitalizations and at least 5 deaths in December 2023 alone. In the US, at least 9 states reported measles cases in the first month of 2024. Even in countries such as Canada, which has eliminated measles cases with vaccination campaigns, new cases have started to be seen, especially due to international travel.
Measles is a highly contagious airborne disease. The virus can remain active in the air or on contaminated surfaces for up to 2 hours. A person carrying the measles virus can infect 9 out of 10 unvaccinated people around them up to 4 days before the appearance of the red rash, the most prominent symptom of the disease.
The World Health Organization (WHO) draws attention to the increase in measles cases in Europe.
According to data from 41 European countries, the number of cases increased from 941 in 2022 to 42,200 in 2023, a 45-fold increase. In the European region, there were more than 200,000 hospitalizations and at least 5 deaths in December 2023 alone. In the first month of 2024, it was announced that measles cases were seen in at least 9 states in the United States. Even in countries such as Canada, which has zeroed out measles cases through vaccination campaigns, new cases have begun to appear, especially due to international travel.
Measles is a respiratory disease and highly contagious. The virus can remain active in the air or on the surface for 2 hours. A person with the measles virus can infect 9 out of 10 unvaccinated people around them up to 4 days before the appearance of red rashes, the most obvious symptom of the disease. #Kızamık #WHO #Measles #sağlıkuyarısı
Activate to view larger image,
Image preview"
----------
PLus https://www.linkedin.com/feed/
Https://www.launchdiagnostics.com/product/measles-solutions/
"Launch Diagnostics LimitedLaunch Diagnostics Limited
1,454 followers1,454 followers
1d • 1d •
Measles cases are experiencing a resurgence in the United Kingdom, with effective testing being crucial for patient management and infection control.
Launch Diagnostics and ACCUSAY offer a wide range of EIA, CLIA and PCR solutions, alongside 3rd party control material to optimise your laboratory’s measles workflow.
All products can be found on the website:
https://lnkd.in/epH_E3t5
For further information, please contact us at enquiries@launchdiagnostics.com or speak to your local territory manager today. "
Fyi https://avacta.com/international-day-of-women-and-girls-in-science/
Sorry important bit truncated .
"Concluding Remarks
Liquid biopsies are of growing importance for the management of cancer and in drug development. This sampling technique has multifaceted utility in the patient care pathway and is less invasive, less costly, and is better suited for real-time longitudinal monitoring compared to the current gold standard, tissue biopsy. Liquid biopsies can be implemented in clinical studies as a fast and accurate method for patient cohort stratification, as an early efficacy-response biomarker, for assessment of clonal evolution and the emergence of treatment resistance. CTCs are emerging as a key component of liquid biopsies that can provide additional transcriptomic insight into clinically relevant biomarkers for a more holistic view of disease status. Furthermore, molecular analysis of liquid biopsies is advancing to provide a rapid and increasingly cost-effective method to evaluate clinically actionable information. "